- ARQ 531 demonstrates substantial anti-tumor activity and manageable safety profile - Eight of nine evaluable CLL patients initially dosed at ≥65 mg experienced a Partial Response (PR) - Five of five CLL patients that were evaluable at the third scan (cycle 9) are durable PRs and continue on
Conference call and webcast with ArQule management to be held on Monday, December 9, 2019 at 8:15 a.m. EST ArQule management to hold an Investor Event on Monday, December 9, 2019 from 8:00-10:00 p.m. EST in Orlando, FL BURLINGTON, Mass. --(BUSINESS WIRE)--Nov. 25, 2019-- ArQule, Inc.
BURLINGTON, Mass. --(BUSINESS WIRE)--Nov. 13, 2019-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London, UK .
ARQ 531 demonstrates substantial anti-tumor activity in refractory CLL patients and manageable safety profile A total of 10 patients experienced partial responses (PRs) as of July 19 th , the cutoff date for data included in the abstract, primarily at the higher doses: 7 with CLL/SLL, 1 with FL, 1
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 30, 2019-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2019. For the quarter ended September 30, 2019 , the Company reported a net loss of $10.7 million , or
Data from a phase 1 clinical trial suggest that circulating tumor DNA (ctDNA) may serve as a reliable biomarker of tumor mutational status and could be used to predict treatment response Preclinical work demonstrates treatment with ARQ 751 in combination with a variety of therapeutic agents
Treatment with miransertib prevents formation of new PIK3CA-driven vascular malformations and leads to regression of existing PIK3CA-driven vascular malformations in experimental mouse model BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 21, 2019-- ArQule , Inc.
BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 16, 2019-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2019 before the market opens on Wednesday, October 30, 2019 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
Two poster presentations on ARQ 751 will highlight data from the phase 1 trial, as well as preclinical studies demonstrating the potential of ARQ 751 in combination with various therapeutic agents BURLINGTON, Mass. --(BUSINESS WIRE)--Oct. 16, 2019-- ArQule , Inc.
These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.